Your browser doesn't support javascript.
loading
Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study.
Kuramitsu, Madoka; Okuma, Kazu; Yamochi, Tadanori; Sato, Tomoo; Sasaki, Daisuke; Hasegawa, Hiroo; Umeki, Kazumi; Kubota, Ryuji; Sobata, Rieko; Matsumoto, Chieko; Kaneko, Noriaki; Naruse, Isao; Yamagishi, Makoto; Nakashima, Makoto; Momose, Haruka; Araki, Kumiko; Mizukami, Takuo; Mizusawa, Saeko; Okada, Yoshiaki; Ochiai, Masaki; Utsunomiya, Atae; Koh, Ki-Ryang; Ogata, Masao; Nosaka, Kisato; Uchimaru, Kaoru; Iwanaga, Masako; Sagara, Yasuko; Yamano, Yoshihisa; Satake, Masahiro; Okayama, Akihiko; Mochizuki, Manabu; Izumo, Shuji; Saito, Shigeru; Itabashi, Kazuo; Kamihira, Shimeru; Yamaguchi, Kazunari; Watanabe, Toshiki; Hamaguchi, Isao.
Afiliação
  • Kuramitsu M; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Okuma K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Yamochi T; Department of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Sato T; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Sasaki D; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Hasegawa H; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Umeki K; Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
  • Kubota R; Division of Molecular Pathology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Sobata R; Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Matsumoto C; Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Kaneko N; Department of Special Testing, SRL Inc., Tokyo, Japan.
  • Naruse I; Department of Special Testing, SRL Inc., Tokyo, Japan.
  • Yamagishi M; Department of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Nakashima M; Department of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Momose H; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Araki K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Mizukami T; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Mizusawa S; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Okada Y; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ochiai M; Department of Quality Assurance and Radiological Protection, National Institute of Infectious Diseases, Tokyo, Japan.
  • Utsunomiya A; Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.
  • Koh KR; Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
  • Ogata M; Blood Transfusion Center, Oita University Faculty of Medicine, Oita, Japan.
  • Nosaka K; Department of Hematology, Kumamoto University of Medicine, Kumamoto, Japan.
  • Uchimaru K; Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Iwanaga M; Department of Frontier Life Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Sagara Y; Japanese Red Cross Kyushu Block Blood Center, Fukuoka, Japan.
  • Yamano Y; Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Satake M; Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
  • Okayama A; Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan.
  • Mochizuki M; Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Izumo S; Division of Molecular Pathology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Saito S; Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan.
  • Itabashi K; Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan.
  • Kamihira S; Nagasaki Harbor Medical Center, ITREC, Nagasaki, Japan.
  • Yamaguchi K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.
  • Watanabe T; Department of Medical Genome Sciences, Laboratory of Tumor Cell Biology, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
  • Hamaguchi I; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan 130hama@niid.go.jp.
J Clin Microbiol ; 53(11): 3485-91, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26292315
ABSTRACT
Quantitative PCR (qPCR) analysis of human T-cell leukemia virus type 1 (HTLV-1) was used to assess the amount of HTLV-1 provirus DNA integrated into the genomic DNA of host blood cells. Accumulating evidence indicates that a high proviral load is one of the risk factors for the development of adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis. However, interlaboratory variability in qPCR results makes it difficult to assess the differences in reported proviral loads between laboratories. To remedy this situation, we attempted to minimize discrepancies between laboratories through standardization of HTLV-1 qPCR in a collaborative study. TL-Om1 cells that harbor the HTLV-1 provirus were serially diluted with peripheral blood mononuclear cells to prepare a candidate standard. By statistically evaluating the proviral loads of the standard and those determined using in-house qPCR methods at each laboratory, we determined the relative ratios of the measured values in the laboratories to the theoretical values of the TL-Om1 standard. The relative ratios of the laboratories ranged from 0.84 to 4.45. Next, we corrected the proviral loads of the clinical samples from HTLV-1 carriers using the relative ratio. As expected, the overall differences between the laboratories were reduced by half, from 7.4-fold to 3.8-fold on average, after applying the correction. HTLV-1 qPCR can be standardized using TL-Om1 cells as a standard and by determining the relative ratio of the measured to the theoretical standard values in each laboratory.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Viral / Vírus Linfotrópico T Tipo 1 Humano / Carga Viral / Reação em Cadeia da Polimerase em Tempo Real Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: J Clin Microbiol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA Viral / Vírus Linfotrópico T Tipo 1 Humano / Carga Viral / Reação em Cadeia da Polimerase em Tempo Real Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: J Clin Microbiol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Japão